Understanding the NSAID related risk of vascular events.
作者信息
Vonkeman Harald E, Brouwers Jacobus R B J, van de Laar Mart A F J
机构信息
Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente Hospital and University of Twente, Enschede, Netherlands.
出版信息
BMJ. 2006 Apr 15;332(7546):895-8. doi: 10.1136/bmj.332.7546.895.
Abstract
摘要
相似文献
1
Understanding the NSAID related risk of vascular events.了解与非甾体抗炎药相关的血管事件风险。
BMJ. 2006 Apr 15;332(7546):895-8. doi: 10.1136/bmj.332.7546.895.
2
Considering cardiovascular risks when using NSAIDs.使用非甾体抗炎药时需考虑心血管风险。
Orthopedics. 2008 May;31(5):468-71. doi: 10.3928/01477447-20110414-08.
3
[Nonsteroidal anti-inflammatory drugs].[非甾体抗炎药]
Nihon Rinsho. 2007 Oct 28;65 Suppl 8:202-8.
4
Cardiovascular toxicity of nonsteroidal anti-inflammatory drugs: moving beyond cyclooxygenase selectivity.非甾体抗炎药的心血管毒性：超越环氧化酶选择性
Expert Rev Clin Pharmacol. 2011 May;4(3):299-302. doi: 10.1586/ecp.11.12.
5
[Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].[抗炎药物的创新——环氧化酶的抑制作用]
Yao Xue Xue Bao. 2005 Nov;40(11):967-9.
6
Non-steroidal anti-inflammatory drugs and cardiovascular risk.非甾体抗炎药与心血管风险。
S Afr Med J. 2007 Jul;97(7):500-3.
7
Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals.非甾体抗炎药在健康人群中的心血管安全性。
Expert Opin Drug Saf. 2010 Nov;9(6):893-903. doi: 10.1517/14740338.2010.501331.
8
Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.环氧化酶-2抑制剂、非甾体抗炎药与心血管风险
Intern Med J. 2006 Dec;36(12):797-8; author reply 798-9. doi: 10.1111/j.1445-5994.2006.01187.x.
9
Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.权衡环氧化酶-2选择性非甾体抗炎药的风险与获益
Gastroenterol Clin North Am. 2009 Jun;38(2):305-14. doi: 10.1016/j.gtc.2009.03.006.
10
Cardiovascular adverse reactions from NSAIDs are more than COX-2 inhibition alone.
Rheumatology (Oxford). 2010 May;49(5):834-6. doi: 10.1093/rheumatology/kep451. Epub 2010 Jan 22.
引用本文的文献
1
Non-steroidal anti-inflammatory drugs and gastroprotection in primary health care users.基层医疗保健使用者中的非甾体抗炎药与胃保护
Med Pharm Rep. 2020 Jul;93(3):246-252. doi: 10.15386/mpr-1533. Epub 2020 Jul 22.
2
Eco-friendly synthesis, characterization, in vitro and in vivo anti-inflammatory activity of silver nanoparticle-mediated aqueous extract.环保型合成、银纳米粒子介导的水提物的表征、体外和体内抗炎活性。
Int J Nanomedicine. 2018 Dec 12;13:8537-8548. doi: 10.2147/IJN.S174530. eCollection 2018.
3
Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue.非甾体抗炎药的心血管风险：一个未得到充分认识的公共卫生问题。
Cureus. 2017 Apr 8;9(4):e1144. doi: 10.7759/cureus.1144.
4
Utilization of gastroprotective strategies for nonsteroidal anti-inflammatory drug-induced gastrointestinal events in a major teaching hospital.在一家大型教学医院中针对非甾体抗炎药引起的胃肠道事件采用胃保护策略。
Ther Clin Risk Manag. 2016 Nov 10;12:1649-1657. doi: 10.2147/TCRM.S119722. eCollection 2016.
5
Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks.非甾体抗炎药：心血管风险概述
Pharmaceuticals (Basel). 2010 Jul 7;3(7):2146-2162. doi: 10.3390/ph3072146.
6
Cardiovascular risk factor analysis in patients with a recent clinical fracture at the fracture liaison service.骨折联络服务中心近期临床骨折患者的心血管危险因素分析
Biomed Res Int. 2014;2014:710945. doi: 10.1155/2014/710945. Epub 2014 Aug 27.
7
Applications of the hexanic fraction of Agave sisalana Perrine ex Engelm (Asparagaceae): control of inflammation and pain screening.龙舌兰麻正己烷馏分的应用：炎症控制和疼痛筛选。
Mem Inst Oswaldo Cruz. 2013 May;108(3):263-71. doi: 10.1590/S0074-02762013000300002.
8
Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential implications for extended influenza vaccination.荷兰流感和呼吸道合胞病毒（RSV）季节期间的过度药物处方：对扩大流感疫苗接种的潜在影响。
Vaccine. 2009 Feb 11;27(7):1119-26. doi: 10.1016/j.vaccine.2008.11.070. Epub 2008 Dec 9.
9
Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis.辉瑞公司研发的昔布类环氧化酶-2（COX2）选择性抑制剂——鲁米昔布治疗疼痛和骨关节炎的疗效和耐受性。
Ther Clin Risk Manag. 2008 Apr;4(2):337-44. doi: 10.2147/tcrm.s1209.
10
Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?选择性 COX-2 抑制剂、非甾体抗炎药和心血管事件——塞来昔布是最安全的选择吗？
Ther Clin Risk Manag. 2007 Oct;3(5):831-45.
本文引用的文献
1
Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.关注声明：庞巴迪等人，《罗非昔布与萘普生对类风湿性关节炎患者上消化道毒性的比较》，《新英格兰医学杂志》2000年；343:1520 - 1528。
N Engl J Med. 2005 Dec 29;353(26):2813-4. doi: 10.1056/NEJMe058314. Epub 2005 Dec 8.
2
Cyclooxygenase inhibition and cardiovascular risk.环氧化酶抑制与心血管风险。
Circulation. 2005 Aug 2;112(5):759-70. doi: 10.1161/CIRCULATIONAHA.105.568451.
3
Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.罗非昔布、塞来昔布及其他非甾体抗炎药使用者发生心肌梗死住院的风险：一项基于人群的病例对照研究。
Arch Intern Med. 2005 May 9;165(9):978-84. doi: 10.1001/archinte.165.9.978.
4
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.在一项预防结直肠腺瘤的临床试验中与塞来昔布相关的心血管风险。
N Engl J Med. 2005 Mar 17;352(11):1071-80. doi: 10.1056/NEJMoa050405. Epub 2005 Feb 15.
5
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.一项结直肠腺瘤化学预防试验中与罗非昔布相关的心血管事件。
N Engl J Med. 2005 Mar 17;352(11):1092-102. doi: 10.1056/NEJMoa050493. Epub 2005 Feb 15.
6
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.使用环氧化酶2选择性和非选择性非甾体抗炎药治疗的患者发生急性心肌梗死和心源性猝死的风险：巢式病例对照研究
Lancet. 2005;365(9458):475-81. doi: 10.1016/S0140-6736(05)17864-7.
7
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.服用罗非昔布和塞来昔布的患者发生非致命性心肌梗死的几率不同。
Ann Intern Med. 2005 Feb 1;142(3):157-64. doi: 10.7326/0003-4819-142-3-200502010-00005.
8
Parecoxib, valdecoxib, and cardiovascular risk.帕瑞昔布、伐地昔布与心血管风险。
Circulation. 2005 Jan 25;111(3):249. doi: 10.1161/01.CIR.0000155081.76164.17. Epub 2005 Jan 17.
9
Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction.停用非甾体抗炎药治疗与急性心肌梗死风险
Arch Intern Med. 2004;164(22):2472-6. doi: 10.1001/archinte.164.22.2472.
10
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.心血管事件风险与罗非昔布：累积荟萃分析
Lancet. 2004;364(9450):2021-9. doi: 10.1016/S0140-6736(04)17514-4.
Zotero 插件